| 摘要 |
The present invention relates to the administration of an HMG-CoA reductase inhibitor, including lovastatin (MEVACOR3) and simvastatin (ZOCOR3), the open-ring dihydroxy acid forms thereof, and salts and esters thereof, and pravastatin (PRAVACHOL3) and fluvastatin (LESCOL3), the closed ring lactone forms and salts and esters thereof, to humans to lower Apolipoprotein E isoform 4 (ApoE isoform 4) levels in the central nervous system to treat, arrest the development of and prevent the onset of Alzheimer's disease.
|
